UPDATE 1-NuVasive Q2 beats estimates, raises 2010 profit view

* Q2 adj EPS $0.42 vs est $0.29

* Q2 rev $119.6 million vs est $117.7 million

* Raises 2010 adj EPS to $1.50-$1.64 from $1.13-$1.25

* Sees 2010 rev $485 mln-$500 mln * Shares up 5 percent after mkt

July 27 (Reuters) - Medical device maker NuVasive Inc (NUVA.O) posted a strong quarterly profit that blew past analyst estimates, helped by increased adoption of its spine treatment, and raised its full-year profit outlook.

"Our strong momentum driven by continued adoption of the XLIF technology and increased traction from our biologics and international areas gives us the confidence to increase guidance," Chief Executive Alex Lukianov said.

For the second quarter, the company reported a net income of $6.7 million, or 17 cents per share, compared with a net income of $2.7 million, or 7 cents per share, a year ago.

Excluding items, it earned 42 cents a share.

Revenue for the quarter rose 35 percent to $119.6 million.

Analysts on average were expecting the company to earn 29 cents a share, excluding items, on revenue of $117.7 million, according to Thomson Reuters I/B/E/S.

The company raised its 2010 profit outlook, excluding items, to a range of $1.50 to $1.64 a share, from its prior view of $1.13 to $1.25 a share.

The company also raised the lower end of its full-year revenue view and now sees full-year revenue at $485 million to $500 million, from $480 million to $500 million.

Analysts on average were expecting adjusted earnings of $1.21 a share, on revenue of $490.3 million.

NuVasive shares rose 5 percent to $35.75 in after-hours trade. They closed at $34.06 Tuesday on Nasdaq. (Reporting by Krishnakali Sengupta in Bangalore; Editing by Unnikrishnan Nair)